{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:30:27Z","timestamp":1782732627396,"version":"3.54.5"},"reference-count":256,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with a poor prognosis. Currently, chemotherapy is the only option for most patients with advanced-stage PDAC. Further, conventional immunotherapies and targeted therapies improve survival outcomes only in rare PDAC patient subgroups. To date, combinatory immunotherapeutic strategies to overcome the immune-hostile PDAC tumor microenvironment (TME) have resulted in limited efficacy in clinical studies. However, efforts are ongoing to develop new treatment strategies for patients with PDAC with the evolving knowledge of the TME, molecular characterization, and immune resistance mechanisms. Further, the growing arsenal of various immunotherapeutic agents, including novel classes of immune checkpoint inhibitors and oncolytic, chimeric antigen receptor T cell, and vaccine therapies, reinforces these efforts. This review will focus on the place of immunotherapy and future possible strategies in PDAC.<\/jats:p>","DOI":"10.3390\/cancers17050715","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T04:53:39Z","timestamp":1740027219000},"page":"715","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6334-4079","authenticated-orcid":false,"given":"Tarik","family":"Demir","sequence":"first","affiliation":[{"name":"Developmental Therapeutics, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Moloney","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2979-9894","authenticated-orcid":false,"given":"Devalingam","family":"Mahalingam","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"Tempero, M.A.M.M., and Benson, A.B. (2024). NCCN Guidelines Version 2.2024 Pancreatic Adenocarcinoma, NCNN."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S2468-1253(23)00207-8","article-title":"The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy","volume":"8","author":"Hilmi","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/14737159.2023.2281482","article-title":"The tumor immune microenvironment in pancreatic cancer and its potential in the identification of immunotherapy biomarkers","volume":"23","author":"Tsunedomi","year":"2023","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1158\/2159-8290.CD-22-0876","article-title":"Context-specific determinants of the immunosuppressive tumor microenvironment in pancreatic cancer","volume":"13","author":"Schneider","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1158\/2159-8290.CD-20-0841","article-title":"Leukocyte heterogeneity in pancreatic ductal adenocarcinoma: Phenotypic and spatial features associated with clinical outcome","volume":"11","author":"Liudahl","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"15095","DOI":"10.1038\/ncomms15095","article-title":"Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer","volume":"8","author":"Carstens","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1053\/j.gastro.2018.08.009","article-title":"Immune cell and stromal signature associated with progression-free survival of patients with resected pancreatic ductal adenocarcinoma","volume":"155","author":"Mahajan","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2018-11-844548","article-title":"Neutrophil plasticity in the tumor microenvironment","volume":"133","author":"Giese","year":"2019","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-06-0369","article-title":"Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions","volume":"12","author":"Hiraoka","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1158\/2159-8290.CD-19-0958","article-title":"Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1158\/1078-0432.CCR-13-0525","article-title":"Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: A role for targeting the CCL2\/CCR2 axis","volume":"19","author":"Sanford","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Plesca, I., Bene\u0161ov\u00e1, I., Beer, C., Sommer, U., M\u00fcller, L., Wehner, R., Heiduk, M., Aust, D., Baretton, G., and Bachmann, M.P. (2022). Clinical significance of tumor-infiltrating conventional and plasmacytoid dendritic cells in pancreatic ductal adenocarcinoma. Cancers, 14.","DOI":"10.3390\/cancers14051216"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","article-title":"The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy","volume":"20","author":"Mensurado","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","article-title":"Neoantigen quality predicts immunoediting in survivors of pancreatic cancer","volume":"606","author":"Sethna","year":"2022","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Hilmi, M., Nicolle, R., Bousquet, C., and Neuzillet, C. (2020). Cancer-Associated Fibroblasts: Accomplices in the Tumor Immune Evasion. Cancers, 12.","DOI":"10.3390\/cancers12102969"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"eabp8964","DOI":"10.1126\/science.abp8964","article-title":"The extracellular matrix and the immune system: A mutually dependent relationship","volume":"379","author":"Sutherland","year":"2023","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1016\/j.cell.2021.09.022","article-title":"Spatially confined sub-tumor microenvironments in pancreatic cancer","volume":"184","author":"Devisme","year":"2021","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1038\/s41467-022-32591-8","article-title":"The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma","volume":"13","author":"Renouf","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"11150","DOI":"10.1200\/JCO.2024.42.16_suppl.11150","article-title":"Mutated KRAS as a promising target in pancreas cancer: PURPLE registry data to inform real-world incidence and prognostic significance and to aid trial recruitment","volume":"42","author":"Lee","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2022.40.4_suppl.591","article-title":"Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI (ON) inhibitor","volume":"40","author":"Gustafson","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ctrv.2019.06.005","article-title":"Checkpoint inhibitors in pancreatic cancer","volume":"78","author":"Henriksen","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2147\/JHC.S322289","article-title":"Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma","volume":"8","author":"Hasanov","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11160","DOI":"10.3748\/wjg.v20.i32.11160","article-title":"Complex role for the immune system in initiation and progression of pancreatic cancer","volume":"20","author":"Inman","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2018.08.033","article-title":"Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features","volume":"155","author":"Puleo","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00535-023-02058-8","article-title":"Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: Real-world data from C-CAT database","volume":"59","author":"Sakakida","year":"2024","journal-title":"J. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"djw283","DOI":"10.1093\/jnci\/djw283","article-title":"The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion","volume":"109","author":"Lu","year":"2017","journal-title":"J. Natl. Cancer. Inst."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","article-title":"Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer","volume":"13","author":"Nomi","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1158\/2326-6066.CIR-21-0144","article-title":"PD-1\/PD-L1-Associated Immunoarchitectural Patterns Stratify Pancreatic Cancer Patients into Prognostic\/Predictive Subgroups","volume":"9","author":"Karamitopoulou","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1200\/JCO.2024.42.3_suppl.640","article-title":"Survival of patients with microsatellite instability-high and Lynch syndrome-associated pancreatic ductal adenocarcinomas","volume":"42","author":"Nasar","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results from the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1200\/JCO.2024.42.16_suppl.4144","article-title":"Somatic mismatch repair deficiency in pancreas cancer (PC): Immune checkpoint blockade (ICB) outcomes and exploratory genomic analyses","volume":"42","author":"Harrold","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/jamaoncol.2017.4182","article-title":"Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers","volume":"4","author":"Prasad","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1200\/JCO.21.01604","article-title":"Overall Survival Results from the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"40","author":"Kindler","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II Study of Maintenance Rucaparib in Patients with Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/jamaoncol.2022.0611","article-title":"Ipilimumab\/Nivolumab Therapy in Patients with Metastatic Pancreatic or Biliary Cancer with Homologous Recombination Deficiency Pathogenic Germline Variants","volume":"8","author":"Terrero","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(22)00369-2","article-title":"Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: A randomised, phase 1b\/2 trial","volume":"23","author":"Reiss","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.hbpd.2018.03.007","article-title":"The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis","volume":"17","author":"Gao","year":"2018","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Macherla, S., Laks, S., Naqash, A.R., Bulumulle, A., Zervos, E., and Muzaffar, M. (2018). Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113505"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Laface, C., Memeo, R., Maselli, F.M., Santoro, A.N., Iaia, M.L., Ambrogio, F., Laterza, M., Cazzato, G., Guarini, C., and De Santis, P. (2023). Immunotherapy and Pancreatic Cancer: A Lost Challenge?. Life, 13.","DOI":"10.3390\/life13071482"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/gutjnl-2020-320726","article-title":"Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: Histology, molecular pathology and clinical implications","volume":"70","author":"Luchini","year":"2021","journal-title":"Gut"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/cjp2.192","article-title":"Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis","volume":"7","author":"McGuigan","year":"2021","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Wang, B., Ran, Z., Liu, M., and Ou, Y. (2019). Prognostic significance of potential immune checkpoint member HHLA2 in human tumors: A comprehensive analysis. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01573"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1158\/1078-0432.CCR-17-2924","article-title":"Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers","volume":"24","author":"Cheng","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Liu, Z., Guo, C., Dang, Q., Wang, L., Liu, L., Weng, S., Xu, H., Lu, T., Sun, Z., and Han, X. (2022). Integrative analysis from multi-center studies identities a consensus machine learning-derived lncRNA signature for stage II\/III colorectal cancer. eBioMedicine, 75.","DOI":"10.1016\/j.ebiom.2021.103750"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41467-023-36296-4","article-title":"Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment","volume":"14","author":"Werba","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Huang, F., Wu, J., Cheng, X., Wang, J., Wen, X., Li, J., Zhang, Q., Jiang, H., Ding, Q., and Zhu, X. (2022). HHLA2 predicts improved prognosis of anti-PD-1\/PD-L1 immunotherapy in patients with melanoma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.902167"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Mortezaee, K. (2023). HHLA2 immune-regulatory roles in cancer. Biomed. Pharmacother., 162.","DOI":"10.1016\/j.biopha.2023.114639"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.canlet.2018.11.007","article-title":"HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival","volume":"442","author":"Yan","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"875","DOI":"10.4251\/wjgo.v16.i3.875","article-title":"Comparison of mismatch repair and immune checkpoint protein profile with histopathological parameters in pancreatic, periampullary\/ampullary, and choledochal adenocarcinomas","volume":"16","author":"Turhan","year":"2024","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1359-6101(01)00038-7","article-title":"The roles of IFN gamma in protection against tumor development and cancer immunoediting","volume":"13","author":"Ikeda","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-13-0458","article-title":"Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation","volume":"4","author":"Bald","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e1008824","DOI":"10.1080\/2162402X.2015.1008824","article-title":"Interferon-\u03b3-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression","volume":"4","author":"Bellucci","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/bjc.2015.101","article-title":"IFN-\u03b3 from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer","volume":"112","author":"Abiko","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e20221952","DOI":"10.1084\/jem.20221952","article-title":"IFN-\u03b3 signature enables selection of neoadjuvant treatment in patients with stage III melanoma","volume":"220","author":"Reijers","year":"2023","journal-title":"J. Exp. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"S1315","DOI":"10.1016\/j.annonc.2021.08.2117","article-title":"LBA39 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-\u03b3 sign): The DONIMI study","volume":"32","author":"Blank","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.annonc.2023.01.004","article-title":"Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials","volume":"34","author":"Versluis","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"101818","DOI":"10.1016\/j.tranon.2023.101818","article-title":"Gene expression profiles (GEPs) of immuno-oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC","volume":"39","author":"Leal","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Sch\u00e4fer, T.E., Knol, L.I., Haas, F.V., Hartley, A., Pernickel, S.C., J\u00e1dy, A., Finkbeiner, M.S., Achberger, J., Arelaki, S., and Modic, \u017d. (2024). Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures. eBioMedicine, 105.","DOI":"10.1016\/j.ebiom.2024.105219"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1158\/2159-8290.CD-20-1202","article-title":"Aggressive PDACs show hypomethylation of repetitive elements and the execution of an intrinsic IFN program linked to a ductal cell of origin","volume":"11","author":"Espinet","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2320280","DOI":"10.1080\/19490976.2024.2320280","article-title":"Roles of microbiota in pancreatic cancer development and treatment","volume":"16","author":"Cruz","year":"2024","journal-title":"Gut Microbes"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"104262","DOI":"10.1016\/j.critrevonc.2024.104262","article-title":"Microbiomes in pancreatic cancer can be an accomplice or a weapon","volume":"194","author":"Guo","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1158\/2159-8290.CD-17-1134","article-title":"The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression","volume":"8","author":"Pushalkar","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1053\/j.gastro.2022.03.054","article-title":"Metagenomic Identification of Microbial Signatures Predicting Pancreatic Cancer from a Multinational Study","volume":"163","author":"Nagata","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"101589","DOI":"10.1016\/j.clinre.2020.101589","article-title":"Microbiome and pancreatic ductal adenocarcinoma","volume":"45","author":"Hilmi","year":"2021","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41586-022-05435-0","article-title":"Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer","volume":"611","author":"Wu","year":"2022","journal-title":"Nature"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccell.2022.01.003","article-title":"Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer","volume":"40","author":"Alam","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"713","DOI":"10.4251\/wjgo.v15.i5.713","article-title":"Intratumour microbiome of pancreatic cancer","volume":"15","author":"Guan","year":"2023","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"C017","DOI":"10.1158\/1538-7445.PANCA2023-C017","article-title":"Abstract C017: The anti-fungal itraconazole improves immunotherapy efficacy in pancreatic ductal adenocarcinoma by reversing the immune-suppressive tumor microenvironment","volume":"84","author":"Porazinski","year":"2024","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e195718","DOI":"10.1001\/jamanetworkopen.2019.5718","article-title":"Associations Between Hepatitis B Virus Infection and Risk of All Cancer Types","volume":"2","author":"Song","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"101691","DOI":"10.1016\/j.canep.2020.101691","article-title":"Hepatitis C virus infection and risk of pancreatic cancer: A meta-analysis","volume":"65","author":"Arafa","year":"2020","journal-title":"Cancer Epidemiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jtho.2018.09.022","article-title":"Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions","volume":"14","author":"Chae","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease\u2014Latest advances and implications for cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.pan.2022.06.009","article-title":"Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma","volume":"22","author":"Ueberroth","year":"2022","journal-title":"Pancreatology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3233\/CBM-230431","article-title":"Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab","volume":"41","author":"Mohamed","year":"2024","journal-title":"Cancer Biomark."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1515\/cclm-2023-1157","article-title":"Circulating tumor DNA: Current implementation issues and future challenges for clinical utility","volume":"62","author":"Hu","year":"2023","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e16365","DOI":"10.1200\/JCO.2024.42.16_suppl.e16365","article-title":"Circulating tumor DNA for recurrence monitoring following resection for pancreas adenocarcinoma","volume":"42","author":"Amini","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1200\/JCO.2024.42.16_suppl.107","article-title":"The potential role of serial circulating tumor DNA (ctDNA) testing after upfront surgery to guide adjuvant chemotherapy for early stage pancreatic cancer: The AGITG DYNAMIC-Pancreas trial","volume":"42","author":"Lee","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"17588359231157651","DOI":"10.1177\/17588359231157651","article-title":"Circulating tumor DNA: Toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma","volume":"15","author":"Topham","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/bs.ai.2023.07.001","article-title":"MHC cross-dressing in antigen presentation","volume":"159","author":"MacNabb","year":"2023","journal-title":"Adv. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ijc.2910430316","article-title":"Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx","volume":"43","author":"Esteban","year":"1989","journal-title":"Int. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/ijc.24484","article-title":"HLA-DR expression is associated with better prognosis in sporadic Australian clinicopathological Stage C colorectal cancers","volume":"125","author":"Walsh","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/bjc.1993.290","article-title":"Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis","volume":"68","author":"Andersen","year":"1993","journal-title":"Br. J. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/CMR.0b013e32832e0bc3","article-title":"Coexpression of major histocompatibility complex class II with chemokines and nuclear NF\u03baB p50 in melanoma: A rational for their association with poor prognosis","volume":"19","author":"Martins","year":"2009","journal-title":"Melanoma Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1038\/ncomms10582","article-title":"Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy","volume":"7","author":"Johnson","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2080329","DOI":"10.1080\/2162402X.2022.2080329","article-title":"MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy","volume":"11","author":"Baleeiro","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0378-1119(99)00365-0","article-title":"Functional and structural diversity of the human Dickkopf gene family","volume":"238","author":"Krupnik","year":"1999","journal-title":"Gene"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cca.2018.11.023","article-title":"Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma","volume":"488","author":"Igbinigie","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"7044","DOI":"10.18632\/oncotarget.6951","article-title":"miR-493 mediated DKK1 down-regulation confers proliferation, invasion and chemo-resistance in gastric cancer cells","volume":"7","author":"Jia","year":"2016","journal-title":"Oncotarget"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"19907","DOI":"10.18632\/oncotarget.4529","article-title":"Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer","volume":"6","author":"Han","year":"2015","journal-title":"Oncotarget"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"104388","DOI":"10.1016\/j.critrevonc.2024.104388","article-title":"Emerging Targeted Therapies and Strategies to Overcome Resistance in Biliary Tract Cancers","volume":"199","author":"Demir","year":"2024","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1172\/JCI88620","article-title":"CKAP4 is identified as a receptor for Dickkopf in cancer cells","volume":"126","author":"Bhavanasi","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Cupp, M.A., Cariolou, M., Tzoulaki, I., Aune, D., Evangelou, E., and Berlanga-Taylor, A.J. (2020). Neutrophil to lymphocyte ratio and cancer prognosis: An umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med., 18.","DOI":"10.1186\/s12916-020-01817-1"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-019-0915-y","article-title":"Neutrophils escort circulating tumour cells to enable cell cycle progression","volume":"566","author":"Szczerba","year":"2019","journal-title":"Nature"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1245\/s10434-018-6941-4","article-title":"Tumor-Infiltrating NETs Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma","volume":"26","author":"Jin","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e146133","DOI":"10.1172\/jci.insight.146133","article-title":"DDR1-induced neutrophil extracellular traps drive pancreatic cancer metastasis","volume":"6","author":"Deng","year":"2021","journal-title":"JCI Insight"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e20190354","DOI":"10.1084\/jem.20190354","article-title":"Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer","volume":"217","author":"Zhang","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Chen, Y., Chen, D., Wang, Q., Xu, Y., Huang, X., Haglund, F., and Su, H. (2021). Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.719105"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: The cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejca.2023.04.012","article-title":"Efficacy of immune checkpoint inhibitors in microsatellite unstable\/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort","volume":"188","author":"Sayah","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1200\/JCO.2018.36.4_suppl.470","article-title":"Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma","volume":"36","author":"Sharma","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J. Immunother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti\u2013PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: A phase 2 randomized clinical trial","volume":"5","author":"Oh","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e007883","DOI":"10.1136\/jitc-2023-007883","article-title":"Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)","volume":"12","author":"Callahan","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Yang, J., Zhang, Q., Wang, J., Lou, Y., Hong, Z., Wei, S., Sun, K., Wang, J., Chen, Y., and Sheng, J. (2022). Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy. eBioMedicine, 78.","DOI":"10.1016\/j.ebiom.2022.103958"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.3748\/wjg.v24.i20.2137","article-title":"Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?","volume":"24","author":"Hilmi","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1158\/0008-5472.CAN-14-0657","article-title":"Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes","volume":"74","author":"Kanterman","year":"2014","journal-title":"Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/annonc\/mdt349","article-title":"Immunological off-target effects of standard treatments in gastrointestinal cancers","volume":"25","author":"Duffy","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1634\/theoncologist.2019-0473","article-title":"Ipilimumab and gemcitabine for advanced pancreatic cancer: A phase Ib study","volume":"25","author":"Kamath","year":"2020","journal-title":"Oncologist"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10637-017-0525-1","article-title":"Phase Ib\/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma","volume":"36","author":"Weiss","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-0099","article-title":"Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer","volume":"26","author":"Wainberg","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","article-title":"Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer","volume":"27","author":"Byrne","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: An open-label, multicentre, phase 1b study","volume":"22","author":"Varadhachary","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: Clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Maurer","year":"2022","journal-title":"Nat. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(24)00263-8","article-title":"Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): A single-arm, multicentre phase 1b\/2 study","volume":"25","author":"Borbath","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Patente, T.A., Pinho, M.P., Oliveira, A.A., Evangelista, G.C.M., Bergami-Santos, P.C., and Barbuto, J.A.M. (2018). Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.03176"},{"key":"ref_124","first-page":"330","article-title":"Interleukin-1\u03b2-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression","volume":"70","author":"Takahashi","year":"2021","journal-title":"Gut"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"eadj5097","DOI":"10.1126\/sciimmunol.adj5097","article-title":"Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1","volume":"8","author":"Wattenberg","year":"2023","journal-title":"Sci. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1158\/1078-0432.CCR-19-0081","article-title":"Mobilization of CD8+ T cells via CXCR4 blockade facilitates PD-1 checkpoint therapy in human pancreatic cancer","volume":"25","author":"Seo","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: The COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat. Med."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Truong, L.-H., and Pauklin, S. (2021). Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches. Cancers, 13.","DOI":"10.3390\/cancers13195028"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/2326-6066.CIR-15-0044","article-title":"CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer","volume":"3","author":"Higuchi","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","article-title":"PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer","volume":"25","author":"Ding","year":"2018","journal-title":"Cell Rep."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00262-021-02849-z","article-title":"PD-1\/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures","volume":"70","author":"Appleton","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-015-0094-9","article-title":"Targeting the indoleamine 2, 3-dioxygenase pathway in cancer","volume":"3","author":"Moon","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jamcollsurg.2007.12.014","article-title":"Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection","volume":"206","author":"Witkiewicz","year":"2008","journal-title":"J. Am. Coll. Surg."},{"key":"ref_134","first-page":"3520","article-title":"Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity","volume":"115","author":"Liu","year":"2010","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/cncr.34512","article-title":"Phase 1\/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors","volume":"129","author":"Naing","year":"2023","journal-title":"Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): A phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"102461","DOI":"10.1016\/j.ctrv.2022.102461","article-title":"Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy","volume":"110","author":"Fujiwara","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_138","unstructured":"US Food and Drug Administration (2020, July 20). FDA Approves Lenvatinib in Combination with Everolimus for Advanced Renal Cell Carcinoma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/lenvatinib-combination-everolimus."},{"key":"ref_139","unstructured":"US Food and Drug Administration (2019, April 20). FDA Approves Pembrolizumab Plus Axitinib for Advanced Renal Cell Carcinoma, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-plus-axitinib-advanced-renal-cell-carcinoma."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","article-title":"Immune modulatory effects of oncogenic KRAS in cancer","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.annonc.2021.01.070","article-title":"Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: Phase III RESOLVE study","volume":"32","author":"Tempero","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.ejca.2014.04.024","article-title":"A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas","volume":"50","author":"Infante","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1200\/JCO.2024.42.3_suppl.673","article-title":"Maintenance therapy with olaparib or selumetinib plus durvalumab (S+D) according to genetic profile of metastatic pancreatic adenocarcinoma (m-PDAC) controlled with modified FOLFIRINOX (mFFX): A phase II randomized MAZEPPA GERCOR D19-02 PRODIGE-72 study","volume":"42","author":"Hammel","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.3748\/wjg.v27.i21.2710","article-title":"Molecular alterations in pancreatic tumors","volume":"27","author":"Visani","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-020-00958-3","article-title":"Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma","volume":"13","author":"Qian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.2024.42.3_suppl.658","article-title":"The interim analysis of a single-arm, open-label, phase II study investigating ALLEN regimen (durvalumab plus albumin paclitaxel and lenvatinib) in patients with metastatic pancreatic cancer (mPC)","volume":"42","author":"Chen","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1200\/JCO.2024.42.3_suppl.659","article-title":"Preliminary results of a phase II study of surufatinib plus sintilimab, nab-paclitaxel and gemcitabine (AG) as first-line therapy in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (mPDAC)","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.2024.42.3_suppl.671","article-title":"Updated results of a phase 1b\/2 study of surufatinib plus camrelizumab, nab-paclitaxel and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC)","volume":"42","author":"Jia","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1200\/JCO.2024.42.3_suppl.665","article-title":"ARC-8: Phase 1\/1b Randomized Study of Quemliclustat + Gemcitabine\/Nab-Paclitaxel \u00b1 Zimberelimab in Patients with Treatment-Naive Metastatic Pancreatic Adenocarcinoma","volume":"42","author":"Wainberg","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3322\/caac.21358","article-title":"Radiotherapy combination opportunities leveraging immunity for the next oncology practice","volume":"67","author":"Herrera","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.2147\/OTT.S311661","article-title":"Near complete pathologic response to PD-1 inhibitor and radiotherapy in a patient with locally advanced pancreatic ductal adenocarcinoma","volume":"14","author":"McCarthy","year":"2021","journal-title":"OncoTargets Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"eadk1827","DOI":"10.1126\/sciadv.adk1827","article-title":"Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells","volume":"10","author":"Wang","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"CT134","DOI":"10.1158\/1538-7445.AM2024-CT134","article-title":"Abstract CT134: Safety and immunologic impact of neoadjuvant\/adjuvant GM-CSF-secreting allogenic pancreatic tumor cell vaccine (GVAX) combined with cyclophosphamide, pembrolizumab, and macrophage-targeting CSF1R inhibitor IMC-CS4 in pancreatic adenocarcinoma","volume":"84","author":"Urman","year":"2024","journal-title":"Cancer Res."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Jarosz-Biej, M., Smolarczyk, R., Cicho\u0144, T., and Ku\u0142ach, N. (2019). Tumor microenvironment as a \u201cgame changer\u201d in cancer radiotherapy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133212"},{"key":"ref_156","first-page":"e168824","article-title":"Potentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancer","volume":"9","author":"Zhang","year":"2024","journal-title":"JCI Insight"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Nisar, M., Paracha, R.Z., Adil, S., Qureshi, S.N., and Janjua, H.A. (2022). An Extensive Review on Preclinical and Clinical Trials of Oncolytic Viruses Therapy for Pancreatic Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.875188"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: Progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Volovat, S.R., Scripcariu, D.V., Vasilache, I.A., Stolniceanu, C.R., Volovat, C., Augustin, I.G., Volovat, C.C., Ostafe, M.-R., Andreea-Voichi\u021ba, S.-G., and Bejusca-Vieriu, T. (2024). Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25021180"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"216456","DOI":"10.1016\/j.canlet.2023.216456","article-title":"Oncolytic adenovirus as pancreatic cancer-targeted therapy: Where do we go from here?","volume":"579","author":"Yoon","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Gurreri, E., Genovese, G., Perelli, L., Agostini, A., Piro, G., Carbone, C., and Tortora, G. (2023). KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202305.0914.v1"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.1038\/cddis.2013.259","article-title":"Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer","volume":"4","author":"Carew","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Mahalingam, D., Goel, S., Aparo, S., Patel Arora, S., Noronha, N., Tran, H., Chakrabarty, R., Selvaggi, G., Gutierrez, A., and Coffey, M. (2018). A Phase II Study of Pelareorep (REOLYSIN(\u00ae)) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers, 10.","DOI":"10.3390\/cancers10060160"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/1078-0432.CCR-19-2078","article-title":"Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study","volume":"26","author":"Mahalingam","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/s41416-023-02344-5","article-title":"Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC)","volume":"129","author":"Mahalingam","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"S899","DOI":"10.1016\/j.annonc.2023.09.2572","article-title":"1623P Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study","volume":"34","author":"Arnold","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"TPS4203","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4203","article-title":"Phase 1\/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX+\/-atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma","volume":"42","author":"Arnold","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"8117","DOI":"10.1007\/s00432-023-04735-w","article-title":"Oncolytic adenoviruses and the treatment of pancreatic cancer: A review of clinical trials","volume":"149","author":"Taylor","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e003255","DOI":"10.1136\/jitc-2021-003255","article-title":"Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors","volume":"10","author":"Macarulla","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"TPS4210","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4210","article-title":"VIRAGE: A phase IIb, open-label, randomized study of nab-paclitaxel and gemcitabine plus\/minus VCN-01 in patients with metastatic pancreatic cancer","volume":"42","author":"Macarulla","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1470-2045(24)00079-2","article-title":"LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): Results from arm 1 of a non-randomised, single-centre, phase 1\/2 study","volume":"25","author":"Musher","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Hajda, J., Lehmann, M., Krebs, O., Kieser, M., Geletneky, K., J\u00e4ger, D., Dahm, M., Huber, B., Sch\u00f6ning, T., and Sedlaczek, O. (2017). A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3604-y"},{"key":"ref_173","unstructured":"Wedge, M.-\u00c8. (2020). Tailoring Oncolytic Viruses for the Treatment of Pancreatic Cancer. [Master\u2019s Thesis, Universit\u00e9 d\u2019Ottawa\/University of Ottawa]."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1684\/ejd.2018.3447","article-title":"Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe","volume":"28","author":"Gutzmer","year":"2018","journal-title":"Eur. J. Dermatol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1017\/ice.2018.358","article-title":"Viral oncolytic immunotherapy in the war on cancer: Infection control considerations","volume":"40","author":"Robilotti","year":"2019","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00595-023-02773-y","article-title":"Current status of vaccine immunotherapy for gastrointestinal cancers","volume":"54","author":"Suzuki","year":"2023","journal-title":"Surg. Today"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/CJI.0b013e31829fb7a2","article-title":"Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer","volume":"36","author":"Le","year":"2013","journal-title":"J. Immunother."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1479-5876-12-175","article-title":"Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer","volume":"12","author":"Shindo","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/cas.12621","article-title":"Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer","volume":"106","author":"Mayanagi","year":"2015","journal-title":"Cancer Sci."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s13063-019-3332-5","article-title":"A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy","volume":"20","author":"Katsuda","year":"2019","journal-title":"Trials"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejca.2022.03.015","article-title":"Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study","volume":"169","author":"Lau","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cell.2013.01.010","article-title":"The role of telomeres in stem cells and cancer","volume":"152","author":"Rudolph","year":"2013","journal-title":"Cell"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/sj.bjc.6603437","article-title":"Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I\/II study","volume":"95","author":"Bernhardt","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S1470-2045(14)70236-0","article-title":"Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): An open-label, randomised, phase 3 trial","volume":"15","author":"Middleton","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1111\/cas.14106","article-title":"Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma","volume":"110","author":"Shima","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","article-title":"A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: Phase I studies of safety and immune induction","volume":"18","author":"Le","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1158\/1078-0432.CCR-19-3978","article-title":"Evaluation of Cyclophosphamide\/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer","volume":"26","author":"Tsujikawa","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1200\/JCO.2022.40.16_suppl.4148","article-title":"A randomized, non-comparative, phase II study of maintenance OSE2101 vaccine alone or in combination with nivolumab (nivo) or FOLFIRI after induction with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): First interim results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY","volume":"40","author":"Hilmi","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev-med-042617-101816","article-title":"Harnessing tumor mutations for truly individualized cancer vaccines","volume":"70","author":"Vormehr","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"90521","DOI":"10.18632\/oncotarget.19361","article-title":"Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: Challenges and opportunities","volume":"8","author":"Xia","year":"2017","journal-title":"Oncotarget"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2022.40.16_suppl.2538","article-title":"Multicenter phase Ib trial in the US of salvage CT041 CLDN18. 2-specific chimeric antigen receptor T-cell therapy for patients with advanced gastric and pancreatic adenocarcinoma","volume":"40","author":"Botta","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Capone, I., Marchetti, P., Ascierto, P.A., Malorni, W., and Gabriele, L. (2018). Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00552"},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Singh, R.P., Hahn, B.H., and Bischoff, D.S. (2021). Interferon Genes Are Influenced by 17\u03b2-Estradiol in SLE. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.725325"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41392-023-01376-w","article-title":"Mechanisms of obesity- and diabetes mellitus-related pancreatic carcinogenesis: A comprehensive and systematic review","volume":"8","author":"Ruze","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"108442","DOI":"10.1016\/j.pharmthera.2023.108442","article-title":"Obesity, cancer, and response to immune checkpoint inhibitors: Could the gut microbiota be the mechanistic link?","volume":"247","author":"Delaye","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1053\/j.gastro.2013.08.018","article-title":"A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice","volume":"145","author":"Philip","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"eabj0486","DOI":"10.1126\/science.abj0486","article-title":"Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis","volume":"373","author":"Ho","year":"2021","journal-title":"Science"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"111947","DOI":"10.1016\/j.celrep.2022.111947","article-title":"GDF15 neutralization restores muscle function and physical performance in a mouse model of cancer cachexia","volume":"42","author":"Song","year":"2023","journal-title":"Cell Rep."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ccell.2022.05.006","article-title":"Exercise-induced engagement of the IL-15\/IL-15R\u03b1 axis promotes anti-tumor immunity in pancreatic cancer","volume":"40","author":"Kurz","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1126\/science.aaz7015","article-title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","volume":"374","author":"Spencer","year":"2021","journal-title":"Science"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1634\/theoncologist.2019-0751","article-title":"Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy","volume":"25","author":"Bilen","year":"2020","journal-title":"Oncologist"},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Sun, Y., Yang, Q., Shen, J., Wei, T., Shen, W., Zhang, N., Luo, P., and Zhang, J. (2021). The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship with the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.745859"},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Ayres Pereira, M., and Chio, I.I.C. (2019). Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies. Genes, 11.","DOI":"10.3390\/genes11010006"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Ho, W.J., Erbe, R., Danilova, L., Phyo, Z., Bigelow, E., Stein-O\u2019Brien, G., Thomas, D.L., Charmsaz, S., Gross, N., and Woolman, S. (2021). Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways. Genome Biol., 22.","DOI":"10.1186\/s13059-021-02363-6"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"104045","DOI":"10.1016\/j.drudis.2024.104045","article-title":"VISTA: A novel checkpoint for cancer immunotherapy","volume":"29","author":"Gao","year":"2024","journal-title":"Drug Discov. Today"},{"key":"ref_212","first-page":"62","article-title":"Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1\/CXCR2 results in antitumor immunity and durable response in pancreatic cancer","volume":"4","author":"Gulhati","year":"2023","journal-title":"Nat. Cancer"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1158\/2159-8290.CD-24-0190","article-title":"Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy","volume":"14","author":"Chand","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"CT001","DOI":"10.1158\/1538-7445.AM2023-CT001","article-title":"Abstract CT001: A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201\/Keynote-942 trial","volume":"83","author":"Khattak","year":"2023","journal-title":"Cancer Res."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T cell therapy for solid tumors: Bright future or dark reality?","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1158\/1538-7445.AM2024-4008","article-title":"DASH CAR-T: Accelerating CD276-targeted immunotherapy for pancreatic cancer","volume":"84","author":"Wang","year":"2024","journal-title":"Cancer Res."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-14-0697","article-title":"Armed oncolytic virus enhances immune functions of chimeric antigen receptor\u2013modified T cells in solid tumors","volume":"74","author":"Nishio","year":"2014","journal-title":"Cancer Res."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"e99573","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.ymthe.2020.02.016","article-title":"Oncolytic adenovirus armed with BiTE, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous tumors","volume":"28","author":"Porter","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1158\/0008-5472.CAN-16-1577","article-title":"Armed oncolytic adenovirus\u2013expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors","volume":"77","author":"Tanoue","year":"2017","journal-title":"Cancer Res."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.ymthe.2017.09.010","article-title":"Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer","volume":"25","author":"Shaw","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"eaaz1863","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"eabn2231","DOI":"10.1126\/scitranslmed.abn2231","article-title":"Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice","volume":"14","author":"Evgin","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jare.2024.01.014","article-title":"The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer","volume":"67","author":"Tang","year":"2024","journal-title":"J. Adv. Res."},{"key":"ref_225","doi-asserted-by":"crossref","unstructured":"Forsberg, E.M., Riise, R., Saellstr\u00f6m, S., Karlsson, J., Als\u00e9n, S., Bucher, V., Hemminki, A.E., Olofsson Bagge, R., Ny, L., and Nilsson, L.M. (2023). Treatment with anti-HER2 chimeric antigen receptor tumor-infiltrating lymphocytes (CAR-TILs) is safe and associated with antitumor efficacy in mice and companion dogs. Cancers, 15.","DOI":"10.3390\/cancers15030648"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in Cancer Immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2022.07.076","article-title":"Combined MEK and STAT3 inhibition uncovers stromal plasticity by enriching for cancer-associated fibroblasts with mesenchymal stem cell-like features to overcome immunotherapy resistance in pancreatic cancer","volume":"163","author":"Datta","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"TPS713","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS713","article-title":"A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma (PDAC)","volume":"42","author":"Hosein","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s40425-019-0573-5","article-title":"STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models","volume":"7","author":"Jing","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Bose, D. (2017). cGAS\/STING Pathway in Cancer: Jekyll and Hyde Story of Cancer Immune Response. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112456"},{"key":"ref_231","doi-asserted-by":"crossref","unstructured":"Qu, T., Li, B., and Wang, Y. (2022). Targeting CD47\/SIRP\u03b1 as a therapeutic strategy, where we are and where we are headed. Biomark. Res., 10.","DOI":"10.1186\/s40364-022-00373-5"},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Chen, C.L., Tseng, P.C., Satria, R.D., Nguyen, T.T., Tsai, C.C., and Lin, C.F. (2022). Role of Glycogen Synthase Kinase-3 in Interferon-\u03b3-Mediated Immune Hepatitis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094669"},{"key":"ref_233","first-page":"4","article-title":"Glycogen synthase kinase 3\u03b2: The nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer","volume":"7","author":"Uehara","year":"2024","journal-title":"Cancer Drug Resist."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/jcb.22881","article-title":"Glycogen synthase kinase-3\u03b2 indirectly facilitates interferon-\u03b3-induced nuclear factor-\u03baB activation and nitric oxide biosynthesis","volume":"111","author":"Kai","year":"2010","journal-title":"J. Cell. Biochem."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4049\/jimmunol.0804033","article-title":"Glycogen synthase kinase-3\u03b2 facilitates IFN-\u03b3-induced STAT1 activation by regulating Src homology-2 domain-containing phosphatase 2","volume":"183","author":"Tsai","year":"2009","journal-title":"J. Immunol."},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Medunjanin, S., Schleithoff, L., Fiegehenn, C., Weinert, S., Zuschratter, W., and Braun-Dullaeus, R.C. (2016). GSK-3\u03b2 controls NF-kappaB activity via IKK\u03b3\/NEMO. Sci. Rep., 6.","DOI":"10.1038\/srep38553"},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Markovska, A., Somers, K., Guillaume, J., Melief, J., Mazar, A., Schmitt, D., Schipper, H., and Boes, M. (2024). Targeted inhibition of glycogen synthase kinase-3 using 9-ING-41 (elraglusib) enhances CD8 T-cell-reactivity against neuroblastoma cells. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-72492-y"},{"key":"ref_238","doi-asserted-by":"crossref","unstructured":"Huntington, K.E., Louie, A.D., Srinivasan, P.R., Schorl, C., Lu, S., Silverberg, D., Newhouse, D., Wu, Z., Zhou, L., and Borden, B.A. (2023). GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer. bioRxiv.","DOI":"10.1101\/2023.02.07.527499"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"e16289","DOI":"10.1200\/JCO.2023.41.16_suppl.e16289","article-title":"Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC)","volume":"41","author":"Mahalingam","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Metropulos, A.E., Munshi, H.G., and Principe, D.R. (2022). The difficulty in translating the preclinical success of combined TGF\u03b2 and immune checkpoint inhibition to clinical trial. eBioMedicine, 86.","DOI":"10.1016\/j.ebiom.2022.104380"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1126\/science.271.5247.350","article-title":"DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1","volume":"271","author":"Hahn","year":"1996","journal-title":"Science"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"8108","DOI":"10.1128\/MCB.25.18.8108-8125.2005","article-title":"Smad4 dependency defines two classes of transforming growth factor \u03b2 (TGF-\u03b2) target genes and distinguishes TGF-\u03b2-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses","volume":"25","author":"Levy","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Principe, D.R., Underwood, P.W., Kumar, S., Timbers, K.E., Koch, R.M., Trevino, J.G., Munshi, H.G., and Rana, A. (2022). Loss of SMAD4 is associated with poor tumor immunogenicity and reduced PD-L1 expression in pancreatic cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.806963"},{"key":"ref_244","doi-asserted-by":"crossref","unstructured":"Tindall, R.R., Bailey-Lundberg, J.M., Cao, Y., and Ko, T.C. (2024). The TGF-\u03b2 superfamily as potential therapeutic targets in pancreatic cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1362247"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12967-021-03182-w","article-title":"NOX4: A potential therapeutic target for pancreatic cancer and its mechanism","volume":"19","author":"Bi","year":"2021","journal-title":"J. Transl. Med."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1016\/j.cell.2021.07.020","article-title":"Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy","volume":"184","author":"Koikawa","year":"2021","journal-title":"Cell"},{"key":"ref_247","doi-asserted-by":"crossref","unstructured":"Henze, J., Tacke, F., Hardt, O., Alves, F., and Al Rawashdeh, W. (2020). Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer. Cancers, 12.","DOI":"10.3390\/cancers12061389"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-20-3392","article-title":"Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors","volume":"27","author":"Molloy","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.drup.2017.07.001","article-title":"A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer","volume":"31","author":"Coppola","year":"2017","journal-title":"Drug Resist. Updates"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1158\/1078-0432.CCR-17-3284","article-title":"Parallel accumulation of tumor hyaluronan, collagen, and other drivers of tumor progression","volume":"24","author":"Li","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.2020.38.4_suppl.638","article-title":"Randomized Phase III Trial of Pegvorhyaluronidase Alfa with Nab-Paclitaxel Plus Gemcitabine for Patients with Hyaluronan-High Metastatic Pancreatic Adenocarcinoma","volume":"38","author":"Tempero","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S2468-1253(22)00167-4","article-title":"Dual \u03b1V-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: A first-in-human, open-label, multicentre, phase 1 study","volume":"7","author":"Dean","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/s41565-020-00782-3","article-title":"Proton-driven transformable nanovaccine for cancer immunotherapy","volume":"15","author":"Gong","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41586-023-05870-7","article-title":"Programmable protein delivery with a bacterial contractile injection system","volume":"616","author":"Kreitz","year":"2023","journal-title":"Nature"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"CT035","DOI":"10.1158\/1538-7445.AM2023-CT035","article-title":"Abstract CT035: Addition of Salmonella-IL2 to FOLFIRINOX for metastatic stage 4 pancreatic cancer nearly doubles median survival","volume":"83","author":"Kavan","year":"2023","journal-title":"Cancer Res."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"e001872","DOI":"10.1136\/jitc-2020-001872","article-title":"Exercise and the immune system: Taking steps to improve responses to cancer immunotherapy","volume":"9","author":"Gustafson","year":"2021","journal-title":"J. Immunother. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/5\/715\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:38:33Z","timestamp":1760027913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/5\/715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":256,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["cancers17050715"],"URL":"https:\/\/doi.org\/10.3390\/cancers17050715","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]}}}